Frespaciguat clinical trials
Also written MK-5475.
How each study uses frespaciguat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses frespaciguat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPDActive, not recruitingPhase 2Merck Sharp & Dohme LLCNCT05612035Written as Frespaciguat
- A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011)CompletedPhase 1Merck Sharp & Dohme LLCNCT06777602Written as [14C] MK-5475
- A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT03744637Written as Frespaciguat
- Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)CompletedPhase 1Merck Sharp & Dohme LLCNCT04370873Written as Frespaciguat
- A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)CompletedPhase 2/3Merck Sharp & Dohme LLCNCT04732221Written as Frespaciguat
- Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)WithdrawnPhase 1Merck Sharp & Dohme LLCNCT04425733Written as Frespaciguat
Codes
What other systems call frespaciguat · ClinicalTrials.gg INT015254
- UNII (FDA) 6DXN080KGBFRESPACIGUATConfirmed FDA, Wikidata
- Wikidata Q124212541frespaciguatConfirmed FDA, Wikidata
- NCI Thesaurus C211739FrespaciguatOne source FDA
- DrugBank DB21683One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6DXN080KGB | FRESPACIGUAT | Confirmed FDA, Wikidata |
| Wikidata | Q124212541 | frespaciguat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C211739 | Frespaciguat | One source FDA |
| DrugBank | DB21683 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.